Koyama K, Ishikawa H, Abe M, Shiose Y, et al. Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate,
exhibits in vitro activity against breast cancer cells expressing HER3 mutations
with and without HER2 overexpression. PLoS One 2022;17:e0267027.
PMID: 35503762